Cure8 research brief
If biologic availability, infusion capacity, or therapeutic drug monitoring are limited where you live, oral JAK inhibitors could offer a practical, effective alternative for moderate‑to‑severe IBD, according to this regionally focused review.
Gastroenterologists and clinicians in resource‑variable Euroasian healthcare settings; adult IBD patients (including those who lack access to biologics) and caregivers; researchers and policymakers interested in treatment access and implementation.
The authors synthesize randomized trials, network meta-analyses, real-world cohorts, and recent practice guidelines to compare JAK inhibitors with biologic classes (anti‑TNF, anti‑integrin, IL‑12/23 inhibitors).
They highlight stronger and faster symptomatic and endoscopic responses for upadacitinib in ulcerative colitis and positive phase III data in Crohn’s disease, alongside logistical advantages of oral dosing, no cold chain, and lack of anti‑drug antibodies.
The review also emphasizes safety considerations reported across studies — notably higher herpes zoster risk that supports pre‑treatment vaccination — and notes that cardiovascular/thromboembolic signals seen in rheumatoid arthritis surveillance have not been clearly reproduced in IBD populations.
Practical framing: the authors propose a regionally tailored framework where the key clinical choice in resource‑limited settings may be between offering a JAK inhibitor or providing no advanced therapy at all, rather than between a JAK inhibitor and routinely available biologics.
This article is a narrative review (structured search through March 2026) and presents a regionally focused framework rather than new trial results. Safety signals from other disease areas (e.g., RA) are discussed but IBD‑specific data are emphasized; pre‑treatment vaccination for herpes zoster is recommended by the authors based on the cited evidence.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
